FOLH1 and prostate cancer: In particular, a prodrug, named mipsagargin, was obtained by conjugating a TG analog to a peptide that is targeted by prostate-specific membrane antigen (PSMA) (Denmeade et al., 2012; Andersen et al., 2015; Doan et al., 2015), which is overexpressed in prostate cancer cells and most tumor endothelial cells.